ACTG A5201 ATAZANAVIR/RITONAVIR AFTER SUSTAINED VIROLOGIC SUPPRESSION

点击翻译按钮获取中文摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The primary purpose of this study is to evaluate the risk of virologic failure in subjects 24 weeks after treatment with ritonavir-boosted atazanavir (ATV/RTV) maintenance therapy alone. Virologic failure is defined as 2 consecutive plasma HIV-1 RNA measurements >200 copies/mL. Subjects with HIV-1 RNA measurements >200 copies mL must return within 30 days for confirmation of virologic failure, at which point real-time genotyping will be performed if the second viral load is >1000 copies/mL. Decisions about future antiretroviral therapy will be made according to current clinical guidelines and may include resumption of previous combination therapy. All subjects who permanently discontinue study treatment on Step 2, including those who change therapy due to virologic failure, will be followed off treatment on study.